DrugPatentWatch Database Preview

Details for Patent: 8,465,765

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,465,765 protect, and when does it expire?

Patent 8,465,765 protects QUILLIVANT XR and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 8,465,765

Title:	Orally effective methylphenidate extended release powder and aqueous suspension product
Abstract:	An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
Inventor(s):	Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ), Perumal; Ashok (Edison, NJ)
Assignee:	Tris Pharma, Inc. (Monmouth Junction, NJ)
Application Number:	13/611,183
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,465,765
Patent Claim Types: see list of patent claims	Compound; Dosage form; Use; Composition; Formulation;

Drugs Protected by US Patent 8,465,765

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nextwave	QUILLIVANT XR	methylphenidate hydrochloride	FOR SUSPENSION, EXTENDED RELEASE;ORAL	202100-001	Sep 27, 2012	AB	RX	Yes	Yes			Y			TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2

International Family Members for US Patent 8,465,765

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011359405
Australia	2017202955
Brazil	112013020537
Canada	2825991
Denmark	2675438
European Patent Office	2675438